Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Outcomes and Survival From an Australian Centre

RAPHAEL SHAMAVONIAN; ERNEST CHENG; JOSH B. KARPES; SHOMA BARAT; NIMA AHMADI; DAVID L. MORRIS

doi:10.21873/anticanres.15776

Article Information

vol. 42 no. 6 2939-2944

DOI

https://doi.org/10.21873/anticanres.15776

PubMed

35641285

Published By

International Institute of Anticancer Research

Print ISSN

0250-7005

Online ISSN

1791-7530

History

Received March 31, 2022
Revision received April 22, 2022
Accepted April 29, 2022
Published online May 31, 2022.

Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

Author Information

RAPHAEL SHAMAVONIAN1,2,
ERNEST CHENG1,3,
JOSH B. KARPES1,3,
SHOMA BARAT1,3,
NIMA AHMADI1,3 and
DAVID L. MORRIS1,3 ⇑

¹Hepatobilliary and Surgical Oncology Unit, Department of Surgery, St. George Hospital, Kogarah, NSW, Australia;
²School of Medicine, University of Notre Dame, Sydney, NSW, Australia;
³St. George and Sutherland Clinical School, University of New South Wales, Sydney, NSW, Australia

Correspondence to: David L. Morris, MB, ChB, FRCS, MD, Ph.D., Hepatobilliary and Surgical Oncology Unit, Department of Surgery, St. George Hospital, University of New South Wales Level 3, Clinical Sciences (Pitney) Building, St George Hospital Kogarah, NSW, 2217, Australia. Tel: +61 291132590, Fax: +61 291133997, e-mail: david.morris{at}unsw.edu.au

View Full Text